Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

We can only hope Big Pharma can/will find/see value in the current/growing Phase II clinical trial pipeline @ Nash Pharmaceuticals, because clearly shareholders have not bought into the mission statement of Breathtec/Nash Pharma management.

In The Real World Of Big Pharma - Nash Buyouts:

Large drug firms have entered the NASH race by acquisition. Gilead Sciences (NASDAQ: GILD) last April shelled out $400 million up front for the rights to a subsidiary of Nimbus Therapeutics that was pursuing a NASH therapeutic. The Nimbus drug NDI-010976 targets an enzyme called Acetyl CoA Carboxylase, or ACC. That enzyme regulates the creation of fatty acids and has a role in some metabolic functions, such as fat buildup—a contributing factor in NASH.

Last September, Allergan (NYSE: AGN) paid $600 million up front for South San Francisco-based Tobira Therapeutics even though Tobira reported underwhelming NASH data in a Phase 2 trial of its drug cenicrivoroc. Tobira pointed out that patients showed enough improvement in fibrosis, or liver scarring, to warrant a Phase 3 clinical trial.

It’s the second time around for Stafford at a Versant-backed company. He and James Veal, now Jecure’s chief scientific officer, were part of the team at Quanticel Pharmaceuticals, a San Diego-based cancer company acquired by Celgene (NASDAQ: CELG) in 2015 for $100 million up front with the potential for as much as $385 million in milestone payments. Brad Bolzon, managing director at Versant, says Stafford approached him with the proposal of a new company pursuing NASH drugs.

https://xconomy.com/san-diego/2017/02/15/with-20m-ucsd-spinout-jecure-to-press-new-attack-on-nash/

Breathtec News @ Nash Pharmaceuticals:

Nash Pharmaceuticals Announces Positive Pre-Clinical Results Showing Lead Compound NP-160 Significantly Reduces NALFD Score and Fibrosis in Non-Alcoholic Fatty Liver Disease

Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in Inflammatory Bowel Disease

Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-135 in Chronic Kidney Disease


http://breathtecbiomedical.com/news/corporate-news/

In fairness. What I do believe is most shareholders of Breathtec are also shareholders of Cannabix. Meaning most are potheads. Pharmaceuticals is not in their wheelhouse as it relates to timelines and/or ability to value a pharma company. Hence, the nuclear fallout since the Reverse Split. Throw in the usual hate by BLO holders and the Bullrun Capital raiding of commoners and we wade in a recipe of disaster for the forseeable future. After years of bullsh*t, commoners remain in the Abyss.

/////AMG

P.S. Cannabix does not get off scott free. BLO/ZF is 60% off its all-time high. Even after being closer to a handheld device than ever before. Many predicted BLO/ZF would be at $4 to $5 at this point. That's 300% or so off target! Furthermore, the ramping up of lab facility equipment @ BLO/ZF says there will be lots more further testing of a Misty West handheld device. Folks on the BLOZF board think law enforcement will be testing the device for roadside service ASAP. Uhhhh Ok....